Local ablative treatment added to ongoing therapy for prostate, bladder and kidney cancers
Tests local ablation alongside ongoing treatment in adults with prostate, bladder or kidney cancer.
Key facts
- Who runs it
- University of California, Davis
- Where
- Sacramento, United StatesSee the site
- Trial code
- Registry title
- Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 5 Dec 2023
- Expected to end
- 15 Jan 2035
- Type of study
- Interventional
- Treatments tested
- Ablative local therapy
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with prostate cancer, urothelial carcinoma or renal cell carcinoma that has spread. A few lesions grow while they stay on their current drug treatment. They get local ablative therapy and keep the drug treatment.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Prostate cancer, urothelial carcinoma or renal cell carcinoma that has spread. No more than 5 growing or new metastatic lesions. All of them must be safely treatable with local ablative therapy.
- Earlier treatment
- At least 1 line of systemic therapy for metastatic disease. At least 3 months of clinical benefit on the most recent line before new lesions appeared. Currently on systemic therapy and able to continue it, with no more than a planned 30-day break for the local therapy.
Main reasons for not taking part
- Medical conditions that rule out local ablative therapy
- Past treatment side effects that limit or prohibit local ablative therapy
- Growing lesions inside the head (intracranial lesions)
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:; Cohort A: prostate cancer; Cohort B: urothelial carcinoma; Cohort C: renal cell carcinoma
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Age ≥18 years at time of consent
- Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy
- ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. [Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment]
- ≤ 5 progressing or new metastatic lesions
- All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist
Who cannot take part
- Medical comorbidities precluding locally ablative therapies
- History of treatment related toxicities that limit or prohibit application of locally ablative therapies
- Progressing intracranial lesions
Where in United States
- University of California - DavisSacramento, United StatesContact: Office of Clinical ResearchTaking people
About the trial
What the trial wants to find out
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
The group in the trial
- Ablative local therapyTreatment being tested
Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
- Plain-language title
- Local ablative treatment added to ongoing therapy for prostate, bladder and kidney cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 June 2026